Introduction
============

Recent global efforts in the fight against human immunodeficiency virus (HIV) have been focused on the virtual elimination of paediatric HIV infection[@R1] and improvements in the so-called cascade of care for the prevention of mother-to-child transmission of HIV (PMTCT). This cascade includes antenatal HIV testing, uptake of maternal antiretroviral therapy (ART), infant antiretroviral prophylaxis and early infant HIV testing.[@R2]

In 2011, Malawi adapted the relevant World Health Organization (WHO) guidelines to design a national, public-health-oriented strategy for PMTCT.[@R3]^,^[@R4] In this strategy, called Option B+, all pregnant and breastfeeding women found infected with HIV are offered lifelong ART, regardless of their CD4+ T-lymphocyte counts or WHO clinical stage. The strategy's development was supported by emerging evidence that universal ART provision in resource-constrained settings could markedly reduce HIV transmission.[@R5]^--^[@R7] The strategy was designed to remove institutional barriers to care, provide maternal health benefits, reduce maternal mortality and increase ART coverage for future pregnancies in high-fertility settings.[@R4] During the strategy's early implementation, ART initiations among pregnant women increased sixfold and the proportions of women who, having initiated ART while pregnant, were still receiving HIV care 12 and 24 months later were 72% and 68%, respectively.[@R8]^,^[@R9]

Although a few studies in large Malawian health facilities have indicated that many mother--infant pairs miss one or more of the four main steps in the cascade of care provided, for PMTCT, by the national HIV programme, the results of such studies cannot be considered nationally representative.[@R10]^,^[@R11] The summary reports produced by Malawi's national HIV programme use data that are aggregated at health-facility level and do not provide insight into individual risk factors associated with the use of the cascade of care for PMTCT. In 2014, the Malawi Ministry of Health began a national evaluation of Malawi's PMTCT programme. Here we present some of the methods, results and conclusions of that evaluation, which aimed to determine the effectiveness of the Option B+ strategy in a nationally-representative sample of mother--infant pairs enrolled at 4--26 weeks postpartum.

Methods
=======

Study setting
-------------

Implementation of the Malawi integrated PMTCT/ART guidelines began in July 2011. In theory, this gave all pregnant and breastfeeding women access to HIV testing, HIV counselling and ART. At the time of HIV status ascertainment, each HIV-infected pregnant woman should be given enough nevirapine to provide her baby with six weeks of prophylaxis from birth. She should also be asked to bring her child, for HIV testing, to a clinic for the care of children younger than five years, known as an under-5 clinic in Malawi, as soon as the course of prophylaxis is complete at an age of six weeks.[@R4]

Study design and sampling
-------------------------

Our aim was to draw a representative sample for national estimates of the ratios of mother-to-child transmission of HIV (MTCT) in Malawi. The sampling frame included all 579 health facilities that provided PMTCT services in Malawi in 2012--2013. We estimated that we would need to enrol at least 3376 HIV-exposed infants to determine the ratio of MTCT at 24 months postpartum reliably. Probability-proportional-to-size selection was used, without replacement, to select the 54 study facilities: 14 rural and nine urban facilities in the North or Central regions and 22 rural and nine urban in the South region. We subjected data obtained at all 54 study facilities to a cross-sectional analysis.

Data collection and laboratory procedures
-----------------------------------------

Between October 2014 and May 2016, women attending under-5 clinics at each of the study facilities were screened for study eligibility. To be enrolled, a woman had to be a mother of or a legal caregiver for an infant aged 4--26 weeks and be willing and able to give informed consent. Information about age, parity, uptake of antenatal care, HIV testing and whether the woman's HIV status had been ascertained during or before the index pregnancy, if ever, was collected in standardized interviews. Whenever possible, interviewers checked the mothers' health booklets to check the accuracy of the mothers' responses. Women who had only discovered that they were HIV-infected through study screening were not asked about their uptake of maternal ART, infant nevirapine prophylaxis or infant HIV testing. After being interviewed, each enrolled woman was tested, within the study facility, for HIV. Maternal HIV testing, which was based on an initial rapid Determine HIV-1/2 test (Alere Medical, Tokyo, Japan) and confirmation with Unigold HIV-1/2 (Trinity Biotech, Bray, Ireland), followed national guidelines.[@R12] The Joint Clinical Research Centre in Kampala, Uganda, performed qualitative tests for HIV-1 deoxyribonucleic acid (DNA), based on COBAS AmpliPrep and version 2.0 of the COBAS TaqMan assay (Roche Diagnostics, Indianapolis, United States of America), on batched dried spots of blood from all identified HIV-exposed infants.

Statistical analyses
--------------------

We focused on five main steps in the PMTCT cascade of care: attendance at an antenatal clinic -- known as step 0; ascertainment of HIV status during antenatal care (step 1); uptake of maternal ART (step 2); use of infant nevirapine prophylaxis (step 3); and HIV testing, before the study, of HIV-exposed infants when more than eight weeks old (step 4). The denominators used to calculate weighted proportions for step 1, steps 2 and 3 and step 4 were, respectively, the total number of mother--infant pairs included in the cohort, the total number of known HIV-infected mothers and the total number of known HIV-infected mothers with infants that were more than eight weeks old, i.e. with infants that should have been tested for HIV. Mothers who claimed to be HIV-negative and were subsequently found negative in the rapid test were categorized as confirmed HIV-uninfected. Similarly, mothers who claimed to be HIV-positive and were subsequently found positive in the rapid test were categorized confirmed HIV-infected. The HIV status of the other mothers was categorized either as missed HIV diagnosis, if the mother claimed to be HIV-negative or not know her HIV status, but was subsequently found positive in the rapid test, or as inconclusive, if the rapid test results were inconclusive. We recorded ratios of MTCT at 4--26 weeks postpartum as the percentage of infants tested for HIV-1 DNA that were found positive. We calculated an overall MTCT ratio and also separate ratios for the mother--infant pairs who had missed none or one or more PMTCT cascade steps or who were categorized as missed HIV diagnosis.

We report unweighted numbers and weighted categorical proportions with 95% confidence intervals (CI). Missing data were treated as additional categories. We used *χ^2^* tests to compare weighted MTCT ratios. We used a weighted multivariable binary logistic regression to identify factors associated with missing steps 1, 2, 3 and/or 4 of the cascade of care or a missed HIV diagnosis. In each model, weighted odds ratios with 95% CI were adjusted for region and maternal age, parity and uptake of antenatal care, at the study site or a different site, to give adjusted odds ratios (aOR). In the models for missed maternal ART uptake, missed nevirapine prophylaxis and missed infant HIV testing, we also adjusted for ascertained maternal HIV status. We also adjusted for maternal ART status and timing in the model for missed uptake of nevirapine prophylaxis and for uptake of nevirapine prophylaxis in the model for missed infant HIV testing. All analyses were conducted using SPSS Statistics 23 (IBM, Chicago, USA), and adjusted for the complex design of the whole national evaluation of Malawi's PMTCT programme. Each observation was weighted according to sampling interval and the probabilities of districts, clusters and subjects being selected.[@R13]

Ethics
------

Ethical approval was provided by Malawi's National Health Sciences Research Committee (\#1262), the United States Centers for Disease Control and Prevention (\#2014--054--7) and the University of Toronto (\#30448). All mothers or caregivers provided written informed consent.

Results
=======

Although 34 637 mothers or caregivers were interviewed and tested for HIV infection, 657 (1.9%) had to be excluded, because of non-eligibility or incomplete data. All 236 (0.7%) caregiver--infant pairs had to be excluded because the caregivers gave inconsistent answers to the questions on PMTCT services. The remaining 33 744 mothers, who attended care with infants aged 4--26 weeks old, were included in our analysis.

Maternal characteristics
------------------------

The characteristics of the enrolled mothers and their uptake of each step in the PMTCT programme are summarized in [Table 1](#T1){ref-type="table"}. All percentages and aOR reported below are weighted values. Mothers' ages ranged from 12 to 53 years; 17 931 (53.8%) were under 25 years of age and 6247 (20.5%) were adolescents aged 12--19 years. Parity ranged from 1 to 14 and 10 943 (30.5%) of the mothers were primiparous.

###### Characteristics of mother--infant pairs visiting clinics for children younger than five years, Malawi, October 2014--May 2016

  Characteristic                                                                       Unweighted no.   Weighted percentage^a^ (95% CI)
  ------------------------------------------------------------------------------------ ---------------- ---------------------------------
  **Location**                                                                                          
  Recorded^b^                                                                          33 744           N/A
  Rural facility in Central or North regions                                           8 991            23.2 (15.0--34.2)
  Urban facility in Central or North regions                                           13 748           20.5 (12.1--32.4)
  Rural facility in South region                                                       6 106            50.9 (37.6--64.1)
  Urban facility in South region                                                       4 899            5.4 (3.6--8.1)
  **Mother's age in years**                                                                             
  Recorded^b^                                                                          33 744           N/A
  ≤ 19                                                                                 6 427            20.5 (19.1--22.1)
  20--24                                                                               11 504           33.3 (32.5--34.1)
  25--29                                                                               7 423            19.7 (15.8--21.1)
  ≥ 30                                                                                 8 315            26.3 (25.2--27.4)
  Unknown^c^                                                                           75               0.2 (0.1--0.3)
  **Age of last born child in weeks**                                                                   
  Recorded^b^                                                                          33 744           N/A
  4--12                                                                                22 170           63.1 (60.2--35.9)
  13--26                                                                               11 574           36.9 (34.1--39.8)
  **Type of last birth**                                                                                
  Recorded^b^                                                                          33 744           
  Singleton                                                                            33 579           99.1 (98.7--99.4)
  Multiple                                                                             165              0.9 (0.6--1.3)
  **Parity**                                                                                            
  Recorded^b^                                                                          33 744           N/A
  1                                                                                    10 943           30.5 (29.0--32.0)
  2--3                                                                                 14 179           39.6 (38.6--40.7)
  4--6                                                                                 7 810            27.1 (25.5--28.7)
  7--9                                                                                 717              2.7 (2.1--3.4)
  ≥ 10                                                                                 31               0.1 (0.1--0.1)
  Unknown^c^                                                                           64               0.2 (0.1--0.3)
  **ANC attendance**                                                                                    
  Recorded^b^                                                                          33 744           N/A
  Did attend ANC during last pregnancy                                                 33 681           99.8 (99.7--99.9)
  Missed ANC uptake                                                                    63               0.2 (0.1--0.3)
  **Site of ANC uptake**                                                                                
  Recorded^b^                                                                          33 744           N/A
  Same site as enrolment site                                                          26 225           76.3 (70.8--81.0)
  Other site                                                                           7 449            23.5 (18.7--29.0)
  Unknown^c^                                                                           70               0.2 (1.2--0.3)
  **HIV status ascertained at ANC**                                                                     
  Recorded^b^                                                                          33 744           N/A
  Found HIV-negative during index pregnancy                                            30 043           88.5 (86.8--90.0)
  Known to be HIV-positive before index pregnancy                                      1 637            6.4 (5.6--7.3)
  Found HIV-positive during index pregnancy                                            1 596            5.1 (4.3--6.2)
  Missed having HIV status ascertained at ANC or unwilling to reveal result            468              2.2 (1.1--4.4)
  **Maternal HIV status 4--26 weeks postpartum**                                                        
  Recorded^b^                                                                          33 744           N/A
  Confirmed HIV-uninfected                                                             30 057           87.5 (85.5--89.0)
  Confirmed HIV-infected                                                               3 233            11.3 (9.8--12.9)
  Newly identified HIV-infected                                                        286              0.9 (0.6--1.2)
  Had inconclusive results                                                             168              0.4 (0.5--0.5)
  **ART status and timing of ART initiation among confirmed HIV-infected**                              
  Recorded^b^                                                                          3 233            N/A
  On ART since before index pregnancy                                                  1 572            54.0 (49.9--57.9)
  On ART, having started during index pregnancy                                        1 475            40.7 (35.6--46.0)
  On ART, having started postpartum                                                    49               1.6 (0.9--2.9)
  Off ART, having started and stopped                                                  34               0.6 (0.3--1.1)
  Off ART and never started                                                            50               1.2 (0.6--2.4)
  Unknown^c^                                                                           53               1.9 (0.7--4.9)
  **Infant nevirapine prophylaxis given to known HIV-exposed infants**                                  
  Recorded^b^                                                                          3 233            N/A
  From birth to an age of 6 weeks                                                      2 676            75.9 (66.3--83.5)
  For less than 6 weeks                                                                323              16.4 (9.5--26.9)
  Missed indicated nevirapine prophylaxis uptake or unwilling to reveal                234              7.7 (6.1--9.6)
  **Uptake of early infant diagnosis among HIV-exposed infants over 8 weeks of age**                    
  Recorded^b^                                                                          1 465            N/A
  Tested at an age of at least 6 weeks                                                 790              53.2 (46.3--60.0)
  Not tested                                                                           675              46.8 (40.0--53.7)
  **HIV status of HIV-exposed infants aged 4--26 weeks**                                                
  Recorded^b^                                                                          3 519            N/A
  HIV-uninfected                                                                       3 345            95.3 (93.6--96.6)
  HIV-infected                                                                         174              4.7 (3.4--6.3)

ANC: antenatal clinic; ART: antiretroviral therapy; CI: confidence interval; HIV: human immunodeficiency virus; N/A: not applicable.

^a^ Weighted according to sampling interval and the probabilities of districts, clusters and subjects being selected.

^b^ Number used as unweighted denominator.

^c^ Unknown because the relevant question was not answered, the recorded answer could not be read or multiple answers were recorded when only one was allowed.

During the index pregnancy, 33 681 (99.8%) of the mothers attended an antenatal clinic (step 0), 33 276 (97.8%) had their HIV status ascertained at such a clinic (step 1) and 26 225 (76.3%) reported that they had attended an antenatal clinic at the site where they were enrolled.

Of the women who reported that they had had their HIV status ascertained at an antenatal clinic, 1637 (6.4%) and 1596 (5.1%) reported that they had been found HIV-positive before and during the index pregnancy, respectively.

HIV testing at the time of our study identified 3519 (12.1%) mothers with HIV infection, including 3233 (11.3%) confirmed HIV infections and 286 (0.9%) missed HIV diagnoses. The latter represented by 244 mothers who had claimed they were HIV-negative and 42 who had claimed not to know their HIV status.

Of the 3233 confirmed HIV-infected women, 3096 (96.3%) were on ART (step 2); 1572 (54.0%) had started ART before the index pregnancy, 1475 (40.7%) during the index pregnancy and 49 (1.6%) postpartum. Thirty-four (0.6%) of the confirmed HIV-infected women had stopped ART and 50 (1.2%) had not started ART. For 53 (1.9%) women the ART status was unknown.

Of the confirmed HIV-infected mothers, 2676 (75.9%) reported giving their infant nevirapine prophylaxis from birth to an age of six weeks (step 3) and 323 (16.4%) had given such prophylaxis for less than six weeks. Although, when they were interviewed, 139 of the 323 had infants that were under six weeks of age. Of the 1465 identified HIV-exposed infants that were older than eight weeks when their mothers were enrolled, 790 (53.2%) had been tested for HIV-1 DNA before the study screening (step 4).

The overall ratio of MTCT at 4--26 weeks, among 3519 HIV-exposed mother--infant pairs, was 4.7%.

Characteristics associated with missed steps
--------------------------------------------

Overall, 468 (2.2%) mothers claimed that they had not had their HIV status ascertained during antenatal care. In multivariable analysis, adolescent mothers (aOR: 4.9; 95% CI: 2.3--10.6) and those aged 20--24 years (aOR: 2.0; 95% CI: 1.4--2.8) were more likely to have missed this step than older mothers and mothers who had had two or three (aOR: 2.1; 95% CI: 1.2--3.7) or at least four (aOR: 2.5; 95% CI: 1.3--4.6) previous deliveries were more likely to have missed this step than primiparous mothers ([Table 2](#T2){ref-type="table"}).

###### Factors associated with missing antenatal testing for HIV infection and with first identification of such infection 4--26 weeks postpartum, Malawi, October 2014--May 2016

  Characteristic                               Unweighted denominator   Missed antenatal HIV testing                     Newly identified HIV infections^a^               
  -------------------------------------------- ------------------------ ------------------------------ ----------------- ------------------------------------ ----------- ----------------
  **Location (*n* = 33 744)**                                                                          NIIM^c^                                                            
  Rural facility in Central or North regions   8 991                    73 (0.8)                                                                              54 (0.6)    0.8 (0.4--1.6)
  Urban facility in Central or North regions   13 748                   80 (0.6)                                                                              96 (0.7)    0.5 (0.2--1.1)
  Rural facility in South region               6 106                    278 (4.6)                                                                             52 (0.9)    1.0 (0.4--2.2)
  Urban facility in South region               4 899                    37 (0.8)                                                                              42 (0.9)    Reference
  **Mother's age in years (*n* = 33 669)**                                                                                                                                
  ≤ 19                                         6 427                    119 (1.9)                      4.9 (2.3--10.6)                                        24 (0.4)    0.6 (0.3--1.3)
  20--24                                       11 504                   232 (2.0)                      2.0 (1.4--2.8)                                         93 (0.8)    1.1 (0.6--2.2)
  25--29                                       7 423                    105 (1.4)                      1.3 (0.8--1.5)                                         66 (0.9)    1.1 (0.6--2.1)
  ≥ 30                                         8 315                    11 (0.1)                       Reference                                              61 (0.7)    Reference
  **Parity (*n* = 33 680)**                                                                                                                                               
  1                                            10 943                   139 (1.3)                      Reference                                              42 (0.4)    1.0 (0.5--2.0)
  2--3                                         14 179                   186 (1.3)                      2.1 (1.2--3.7)                                         148 (1.0)   2.0 (1.2--3.6)
  ≥ 4                                          8 558                    143 (1.7)                      2.5 (1.3--4.6)                                         54 (0.6)    Reference
  **ANC attendance (*n* = 33 744)**                                                                    NIIM^d^                                                            NIIM^d^
  Yes                                          33 681                   425 (1.3)                                                                             244 (0.7)   
  No                                           63                       43 (68.3)                                                                             0 (0.0)     
  **Location of ANC (*n* = 33 674)**                                                                                                                                      
  At study site                                26 225                   349 (1.3)                      Reference                                              163 (0.6)   Reference
  At different site                            7 449                    77 (1.0)                       0.7 (0.3--1.9)                                         81 (1.1)    2.2 (1.5--3.1)

ANC: antenatal clinic; aOR: adjusted odds ratio; CI: confidence interval; HIV: human immunodeficiency virus; NIIM: not included in model.

^a^ Mother missed HIV diagnosis, she claimed to be HIV-negative or not to know her HIV status, but was found infected in the study.

^b^ Weighted according to sampling interval and the probabilities of districts, clusters and subjects being selected and adjusted for all other variables in the model.

^c^ Excluded from model because of skewed data caused by three rural health facilities in South region having no test kits available when women would have been seeking antenatal care.

^d^ Too few events to be included in the model.

Of the 3519 HIV-infected women identified at screening, 286 (7.1%) had missed being diagnosed earlier. Such missed diagnosis was associated with having attended an antenatal clinic somewhere other than the study site (aOR: 2.2; 95% CI: 1.5--3.1) and with parity, with an aOR of 2.0 (95% CI: 1.2--3.6) for a parity of 2--3 compared with one of at least 4 ([Table 2](#T2){ref-type="table"}).

Fifty (1.2%) of the 3233 confirmed HIV-infected women had not started ART ([Table 3](#T3){ref-type="table"}). Not having started ART was associated with having attended an antenatal clinic somewhere other than the study site (aOR: 4.7; 95% CI: 1.5--14.8) and with having been diagnosed with HIV during, rather than before, the index pregnancy (aOR: 3.2; 95% CI: 1.3--8.0).

###### Factors associated with mothers known to be infected with HIV missing their uptake of antiretroviral therapy or missing nevirapine prophylaxis for their infants, Malawi, October 2014--May 2016

  Characteristic                                                                                   Unweighted denominator   Missed maternal ART uptake^a^                     Missed infant nevirapine prophylaxis^a^               
  ------------------------------------------------------------------------------------------------ ------------------------ ------------------------------- ----------------- ----------------------------------------- ----------- ------------------
  **Location (*n* = 3 233)**                                                                                                                                                                                                        
  Rural facility in Central or North regions                                                       803                      9 (1.1)                         1.5 (0.6--4.0)                                              63 (7.8)    1.5 (0.8--3.0)
  Urban facility in Central or North regions                                                       857                      19 (2.2)                        0.8 (0.3--2.3)                                              69 (8.1)    1.1 (0.5--2.4)
  Rural facility in South region                                                                   881                      9 (1.0)                         1.3 (0.4--4.4)                                              59 (6.7)    1.3 (0.6--2.5)
  Urban facility in South region                                                                   692                      13 (1.9)                        Reference                                                   43 (6.2)    Reference
  **Mother's age in years (*n* = 3 224)**                                                                                                                                                                                           
  ≤ 19                                                                                             191                      3 (1.6)                         1.5 (0.1--14.1)                                             20 (10.5)   1.9 (0.7--4.8)
  20--24                                                                                           617                      16 (2.6)                        1.2 (0.2--5.6)                                              60 (9.7)    3.1 (1.8--5.5)
  25--29                                                                                           790                      14 (1.8)                        0.6 (0.1--3.3)                                              52 (6.6)    1.8 (1.4--2.4)
  ≥ 30                                                                                             1626                     17 (1.0)                        Reference                                                   100 (6.2)   Reference
  **Parity (*n* = 3 230)**                                                                                                                                                                                                          
  1                                                                                                401                      8 (2.0)                         1.8 (0.4--8.5)                                              40 (10.0)   0.5 (0.2--1.2)
  2--3                                                                                             1328                     27 (2.0)                        1.1(0.3--3.2)                                               95 (7.2)    0.6 (0.2--1.5)
  ≥ 4                                                                                              1501                     15 (1.0)                        Reference                                                   98 (6.5)    Reference
  **ANC uptake (*n* = 3 233)**                                                                                                                              NIIM^c^                                                                 NIIM
  Yes                                                                                              3225                     50 (1.6)                                                                                    233 (7.2)   
  No                                                                                               8                        0 (0.0)                                                                                     1 (12.5)    
  **Location of ANC (*n* = 3 225)**                                                                                                                                                                                                 
  At study site                                                                                    2559                     24 (0.9)                        Reference                                                   172 (6.7)   Reference
  At different site                                                                                666                      26 (3.9)                        4.7 (1.5--14.8)                                             61 (9.2)    1.9 (1.1--3.3)
  **HIV status ascertained at ANC**^a^ **(*n* = 3 233)**                                                                                                                                                                            
  Known HIV-positive before index pregnancy                                                        1637                     9 (0.5)                         Reference                                                   100 (6.1)   Reference
  Found HIV-positive during index pregnancy                                                        1596                     41 (2.6)                        3.2 (1.3--8.0)                                              134 (8.4)   0.8 (0.5--1.6)
  **ART status and timing of ART initiation among confirmed HIV-infected mothers (*n* = 3 180)**                                                                                                                                    
  On ART since before index pregnancy                                                              1572                     N/A                             N/A                                                         92 (5.9)    Reference
  On ART, having started during index pregnancy                                                    1475                     N/A                             N/A                                                         76 (5.2)    0.6 (0.3--1.3)
  On ART, having started postpartum                                                                49                       N/A                             N/A                                                         5 (10.2)    1.4 (0.3--6.5)
  Off ART, having started and stopped                                                              34                       N/A                             N/A                                                         7 (20.6)    6.4 (1.5--28.0)
  Off ART and never started                                                                        50                       50 (100)                        N/A                                                         23 (46.0)   15.4 (7.2--32.9)

ANC: antenatal clinic; aOR: adjusted odds ratio; ART: antiretroviral therapy; CI: confidence interval; HIV: human immunodeficiency virus; N/A: not applicable; NIIM: not included in model.

^a^ As reported by mothers 4--26 weeks postpartum.

^b^ Weighted according to sampling interval and the probabilities of districts, clusters and subjects being selected and adjusted for all other variables in the model.

^c^ Too few (0) events to be included in the model.

Among all known HIV-exposed infants, 234 (7.7%) had reportedly not received any nevirapine prophylaxis ([Table 3](#T3){ref-type="table"}). An infant that had missed prophylaxis was more likely to have: (i) a mother aged 20--24 (aOR: 3.1; 95% CI: 1.8--5.5) or 25--29 (aOR: 1.8; 95% CI: 1.4--2.4) years than one older than 30 years; (ii) a mother who had attended an antenatal clinic somewhere other than the study site than a mother who had received antenatal care at the study site (aOR: 1.9; 95% CI: 1.1--3.3); and (iii) a mother who had either stopped ART (aOR: 6.4; 95% CI: 1.5--28.0) or never started ART (aOR: 15.4; 95% CI: 7.2--32.9) than a mother on ART.

Overall, 675 (46.8%) of all known HIV-exposed infants that were older than eight weeks when their mothers were interviewed had reportedly not been tested for HIV-1 DNA at that time ([Table 4](#T4){ref-type="table"}). Mothers with infants that had not been tested were more likely to be younger than 19 years (aOR: 6.9; 95% CI: 1.2--38.9) or aged 20--24 (aOR: 2.7; 95% CI: 1.3--5.6) or 25--29 years (aOR: 1.8; 95% CI: 1.1--3.0) than to be aged at least 30 years. They were also more likely to have a parity of at least 4 (aOR: 3.3; 95% CI: 1.1--10.1) than be primiparous, to have stopped (aOR: 7.7; 95% CI: 2.2--27.0) or never started ART (aOR: 13.7; 95% CI: 4.2--83.3) than to be on ART and to have given no nevirapine prophylaxis to their infants than to have given such prophylaxis (aOR: 2.0; 95% CI: 1.2--3.4; [Table 4](#T4){ref-type="table"}).

###### Factors associated with missed infant virological testing among infants over 8 weeks of age who had been born to mothers known to be HIV infected, Malawi, October 2014--May 2016

  Characteristic                                                                                   Unweighted denominator   Missed infant testing^a^   
  ------------------------------------------------------------------------------------------------ ------------------------ -------------------------- ------------------
  **Location (*n* = 1 465)**                                                                                                                           
  Rural facility in Central or North regions                                                       344                      166 (48.3)                 1.3 (0.5--3.3)
  Urban facility in Central or North regions                                                       402                      146 (36.3)                 0.8 (0.5--1.5)
  Rural facility in South region                                                                   444                      251 (56.5)                 1.6 (0.9--3.0)
  Urban facility in South region                                                                   275                      112 (40.7)                 Reference
  **Mother's age in years (*n* = 1 462)**                                                                                                              
  ≤ 19                                                                                             87                       48 (55.2)                  6.9 (1.2--38.9)
  20--24                                                                                           272                      130 (47.8)                 2.7 (1.3--5.6)
  25--29                                                                                           366                      174 (47.5)                 1.8 (1.1--3.0)
  ≥ 30                                                                                             737                      322 (43.7)                 Reference
  **Parity (*n* = 1 464)**                                                                                                                             
  1                                                                                                179                      82 (45.8)                  Reference
  2--3                                                                                             586                      253 (43.2)                 1.4 (0.6--3.3)
  ≥ 4                                                                                              699                      340 (48.6)                 3.3 (1.1--10.1)
  **ANC uptake (*n* = 1 465)**                                                                                                                         NIIM
  Yes                                                                                              1460                     674 (46.2)                 
  No                                                                                               5                        1 (20.0)                   
  **ANC location (*n* = 1 459)**                                                                                                                       
  At study site                                                                                    1109                     505 (45.5)                 Reference
  At different site                                                                                350                      168 (48.0)                 0.9 (0.6--5.6)
  **HIV status ascertained at ANC (*n* = 1 465)**                                                                                                      
  Known HIV-positive before index pregnancy                                                        724                      312 (43.1)                 Reference
  Found HIV-positive during index pregnancy                                                        741                      363 (49.0)                 1.8 (0.6--1.4)
  **ART status and timing of ART initiation among confirmed HIV-infected mothers (*n* = 1 435)**                                                       
  On ART since before index pregnancy                                                              692                      297 (42.9)                 Reference
  On ART, having started during index pregnancy                                                    672                      303 (45.1)                 0.7 (0.2--2.1)
  On ART, having started postpartum                                                                23                       8 (34.8)                   0.2 (0.1--0.8)
  Off ART, having started and stopped                                                              21                       18 (85.7)                  7.7 (2.2--27.0)
  Off ART and never started                                                                        27                       23 (85.2)                  13.7 (4.2--83.3)
  **Infant nevirapine prophylaxis given to known HIV-exposed infants (*n* = 1 465)**                                                                   
  From birth to an age of 6 weeks                                                                  1241                     522 (42.1)                 Reference
  For less than 6 weeks                                                                            95                       49 (51.6)                  0.8 (0.4--1.4)
  Not given or unknown                                                                             129                      104 (80.6)                 2.0 (1.2--3.4)

ANC: antenatal clinic; aOR: adjusted odds ratio; ART: antiretroviral therapy; CI: confidence interval; HIV: human immunodeficiency virus; NIIM: not included in model.

^a^ As reported by mothers at least 8 weeks postpartum.

^b^ Weighted according to sampling interval and the probabilities of districts, clusters and subjects being selected and adjusted for all other variables in the model.

Programme use and MTCT
----------------------

The relationship between MTCT ratios and the missing of one or more steps in the cascade of care is illustrated in [Fig. 1](#F1){ref-type="fig"}. Among the mothers who missed HIV diagnosis, the MTCT ratio was 22.0% (66/286; 95% CI: 16.6--28.4). Of the 3233 confirmed HIV-infected mothers, 2613 (74.7%; 95% CI: 64.6--82.7) completed steps 1--3. The MTCT ratio for these 2613 mothers was 3.6% (66/2613; 95% CI: 1.8--7.3). Among the 1435 mothers who, when interviewed, had known HIV-exposed infants older than eight weeks, 711 (39.2%; 95% CI: 32.4--46.4) completed steps 1--4. The MTCT ratio for these 711 mothers was 5.7% (19/711; 95% CI: 1.8--16.7).

![Ratio of mother-to-child transmission of HIV, as recorded 4--26 weeks postpartum, Malawi, October 2014--May 2016](BLT.17.203265-F1){#F1}

Among the 50 mothers who missed step 2, MTCT was 7.7% (6/50; 95% CI: 2.5--21.2). Steps 2 and 3 were both missed by 23 (0.7%; 95% CI: 0.3--1.6) mothers and their MTCT ratio was 10.7% (5/23; 95% CI: 3.1--31.3). Just 14 (1.2%; 95% CI: 0.5--3.1) of the 1435 mothers who, when interviewed, had known HIV-exposed infants aged over eight weeks had reportedly missed steps 2--4 and their MTCT ratio was 11.4% (4/14; 95% CI: 3.0--35.2).

The MTCT ratio among mothers who had missed HIV diagnosis was significantly higher than that among mothers who had completed steps 1--3 (*P* \< 0.01) or 1--4 (*P* \< 0.01) or missed step 2 (*P* = 0.04). None of the other differences seen between MTCT ratios, e.g. between mothers who had completed and missed steps or between mothers who had missed HIV diagnosis and those who had missed steps 2--3 or 2--4, reached statistical significance.

Discussion
==========

We estimated that 12.1% of infants of women attending under-5 clinics across Malawi were HIV-exposed. This value is higher than an aggregated estimate (8.1%) based on data collected in antenatal-care facilities across Malawi,[@R8] but consistent with the prevalence of HIV infection reported among women aged 15--49 years (12.1%) as part of the recent HIV impact assessment in Malawi.[@R14]

The high uptake of PMTCT services we report aligns with estimates produced by the health minstry.[@R14]^,^[@R15] The PMTCT uptake was similar across regions or between rural and urban sites. Our results add to the evidence indicating that, within Malawi, the scale-up of the implementation of the Option B+ strategy has provided widely decentralized and equitable coverage of PMTCT services.[@R8]^,^[@R16]

The elimination of paediatric HIV infections will probably depend on the full use of PMTCT services.[@R17]^--^[@R19] In South Africa, a third of early infant HIV infections were attributed to the missing of one or more steps in the PMTCT cascade of care and, as observed in our study, the MTCT ratio increased as more steps were missed.[@R10]

We found that young women and adolescent girls were particularly prone to missing antenatal HIV testing. Data previously collected in Kenya,[@R20] Malawi,[@R21] and South Africa[@R10]^,^[@R22] indicated that adolescents were especially likely to miss parts of the PMTCT cascade.[@R10]^,^[@R20]^--^[@R22] In our study, adolescents found HIV-positive usually started ART and infant nevirapine prophylaxis, but often missed infant HIV testing. Further research is needed to improve our understanding of the retention of, and outcomes among, young women and to assess the potential benefits of youth-friendly initiatives such as peer-support groups for pregnant adolescents.

We identified a substantial number of women who missed HIV diagnosis during the index pregnancy and these were associated with a relatively high MTCT ratio. Some of these women may have had the very high viral loads during acute HIV infection that are strongly associated with MTCT.[@R23] We need more research on the identification and engagement of this high-risk subgroup.

The impact of service integration and timing of HIV diagnosis on uptake of ART was demonstrated by the fact that HIV-infected women were relatively unlikely to be on ART if they had received antenatal care at a different facility to the one hosting the under-5 clinic they attended and if they had been found HIV-infected during, rather than before, the index pregnancy. In earlier studies in Malawi, a facility's model of care was found to influence mothers' engagement in the PMTCT cascade[@R24] and retention on ART has been found to be relatively poor in facilities where women were asked to initiate ART on the same day that they discovered they were HIV-infected.[@R25] For the women involved, HIV diagnosis during pregnancy and the concept of life-long treatment are both challenging.[@R26]^,^[@R27] Further understanding of the impact of a HIV diagnosis during pregnancy and of the optimal model of care is required.

In our study, around a quarter of HIV-exposed infants did not receive the full six-week course of nevirapine prophylaxis and almost half of the HIV-exposed infants above eight weeks of age had not been tested for HIV-1 DNA. Delayed or missed infant HIV diagnoses, which have previously been highlighted as key challenges in Malawi,[@R8]^,^[@R28] lead to delayed ART and place HIV-infected infants at high risk.

If we project our findings to the Malawian population and burden of HIV, we estimate that, in 2017, about 16 874 Malawian women, i.e. 2.2% of the 767 000 Malawian women who gave birth,[@R29] did not receive antenatal HIV testing. If we assume a 12.1% prevalence of HIV infection among the fertile women,[@R14] we can estimate that 92 807 pregnant Malawian women were HIV-infected, including 6589 (7.1%) who missed HIV diagnosis in pregnancy. Among the women who knew that they were HIV-positive when pregnant, an estimated 1035 (1.2%) will not have started ART, 6639 (7.7%) of their infants will not have received any nevirapine prophylaxis and 40 350 (46.8%) of their infants will not have been tested for HIV-1 DNA after they were aged six weeks. An estimated 69 327 (74.7%) of the mothers will have received antenatal HIV testing and, if found infected, started maternal ART and given nevirapine prophylaxis to their infants, of whom an estimated 2496 (3.6%) will have been infected. Among the 6589 mothers who missed HIV diagnosis, 1450 (22.0%) will have transmitted HIV to their infants. Based on our findings and these projections, the focus of future targeted interventions needs to be on reducing the numbers of missed HIV diagnoses in pregnancy and increasing the proportion of HIV-exposed infants tested for HIV-1 DNA.

The large sample size and the study's national representativeness are strengths of this study. However, by screening at under-5 clinics, we may have biased our sample towards women who usually take up health care. We made no attempt to recruit women who do not attend clinics and those with infants who died younger than four weeks. As a result, our estimates of the use of the PMTCT programme may be too high. We also acknowledge the potential for responder bias in terms of reported uptake of services, although interviewers checked mothers' health booklets to confirm responses. Lastly, as some of the numbers in the subgroup analyses were small, the reported confidence intervals are wide and need to be interpreted with care. The same small numbers limited the statistical significance of the between-subgroup differences seen in MTCT ratios.

In conclusion, the scale-up of Option B+ services appears to have provided universal access to PMTCT care. The findings that young maternal age, high parity and use of services at different clinics were associated with incomplete care should help to guide the development of interventions to accelerate progress towards the elimination of MTCT from Malawi.

This study was supported by the President's Emergency Plan for AIDS Relief through the United States Centers for Disease Control and Prevention and under the terms of a co-operative agreement (U2GGH000721-02).

None declared.
